{"id":"258845020786-10","name":"Gilead Sciences","registrationDate":"2016-02-23T17:12:58.644+01:00","category":2,"subCategory":3,"legal":"Corporation","web":"http://www.gilead.com","country":"United states","headAddress":"333 Lakeside","headCity":"California","headPostCode":"CA94404","headPhone":"(1)65 05 74 30 00","boss":"Alton  Gregg","bossTitle":"Mr","bossPosition":"Interim Chief Executive Officer","membersCount":3,"membersFTE":"1.25","membership":"AMCHAM EU: http://www.amchameu.eu&#xd;\n&#xd;\nEuropabio http://www.europabio.org &#xd;\n&#xd;\nEUCOPE http://www.eucope.org","memberOrga":"","goal":"Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The companyâ€™s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide.","acronym":"GILD","interests":"Business and Industry, Competition, Economy, finance and the euro, Public Health, Trade","euInitiatives":"EU initiatives in relation to HIV/AIDS, Hepatitis B &amp; C and oncology. Joint Action on HIV and co-infection prevention and harm reduction.&#xd;<br />&#xd;<br />- ATMP Regulation&#xd;<br />- EU IP policy&#xd;<br />- EU Relative Efficacy Assessment (EU REA)&#xd;<br />- EU research policy &#xd;<br />- EU trade policy&#xd;<br />- Health Systems Performance Assessment&#xd;<br />- Health Technology Assessment &amp; Market Access&#xd;<br />- Industrial policy&#xd;<br />- Outcomes-based healthcare systems&#xd;<br />- Paediatric Regulation&#xd;<br />- Sustainable Development Goals","lastUp":"2019-02-15T16:12:44.706+01:00","customers":"","costAbsolu":"","costRange":"400000-499999","turnoverAbsolu":0,"turnoverRange":""}